News and Events

March 12, 2024

NIH opens Long COVID trials to evaluate treatments for autonomic nervous system dysfunction

RECOVER-AUTONOMIC will test at least three treatments for symptoms such as fast heart rate, dizziness and fatigue.

February 13, 2024

Leadership Q&A: NIH to bolster RECOVER Long COVID research efforts

Gary Gibbons, M.D., Walter Koroshetz, M.D., and Jeanne Marrazzo, M.D., M.P.H. of the NIH answer questions about investing an additional $515 million in RECOVER's Long COVID research efforts.

February 13, 2024

NIH to bolster RECOVER Long COVID research efforts through infusion of $515 million

This additional funding will build on and continue RECOVER's work to improve our understanding of and ability to diagnose, prevent, and treat Long COVID.

October 31, 2023

Now Available: Dataset for “Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection”

Authorized researchers may request access to the dataset, which contains more than 3.3 million de-identified data entries and a Data Dictionary.

October 3, 2023

Changes in the body provide clues for the development of Long COVID

A research team that includes RECOVER researchers found changes in the immune systems of people with Long COVID.

September 5, 2023

RECOVER-NEURO enrolls first participant in trial

RECOVER-NEURO will enroll 315 people and test several different treatments for Long COVID patients who have difficulty focusing, thinking clearly, and remembering things.

July 31, 2023

NIH launches long COVID clinical trials through RECOVER Initiative, opening enrollment

Initially, RECOVER will test at least four potential treatments for Long COVID, with test of seven more treatments expected in the coming months.

July 31, 2023

RECOVER-VITAL enrolls first participant in trial

RECOVER-VITAL will enroll 900 people over the next six months and seek to understand whether taking Paxlovid, an antiviral drug, can improve Long COVID symptoms caused by viral persistence.